CLAIMS

1. A compound which comprises a modified oligonucleotide consisting of 12-30 linked nucleosides, at least a 12 nucleobase sequence portion of which is complementary to nucleotides present within the region selected from nucleotides 1399-1423, 1388-1423, and 1394-1423 of SEQ ID NO: 9, wherein the modified oligonucleotide comprises:

(a) a gap segment consisting of linked deoxynucleosides;

(b) a 5' wing segment consisting of linked modified nucleosides; and

(c) a 3' wing segment consisting of linked modified nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each modified nucleoside within each wing segment comprises a modified sugar .

2. The compound of claim 1, wherein the at least 12 nucleobase sequence portion is complementary to nucleotides present within the region 1399-1423.

3. The compound of claim 1 or claim 2, wherein the compound comprises a modified oligonucleotide consisting of 12-30 linked nucleosides, at least a 12 nucleobase sequence portion of which is present within the nucleobase sequences set forth in SEQ ID NOs: 39, 40, and 166.

4. The compound of claim 3, wherein the at least 12 nucleobase sequence portion is present within the nucleobase sequence set forth in SEQ ID NO: 39.

5. The compound of any one of claims 1 to 4, wherein the modified oligonucleotide consists of 20 linked nucleosides.

6. The compound of any one of claims 1 to 3 or 5, wherein the modified oligonucleotide has a sequence which is 100% identical over its length to a portion of one of the sequences set forth in SEQ ID NOs: 39, 40, and 166.

7. The compound of claim 6, wherein the modified oligonucleotide has a sequence which is 100% identical over its length to a portion of the sequence set forth in SEQ ID NO: 39.

8. The compound of any one of claims 1 to 7, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.

9. The compound of claim 8, wherein at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage.

10. The compound of claim 8, wherein each modified internucleoside linkage is a phosphorothioate linkage.

11. The compound of claim 8 or 10, wherein each internucleoside linkage which is not modified is a phosphodiester linkage.

12. The compound of claim 8, wherein each internucleoside linkage is modified and is a phosphorothioate linkage.

13. The compound of any one of claims 1-12, wherein at least one nucleoside comprises a modified sugar.

14. The compound of claim 13, wherein the modified sugar is a bicyclic sugar.

15. The compound of claim 13, wherein at least one of the modified sugar comprises a 2'-O-methoxyethyl.

16. The compound of any one of claims 1-12, comprising at least one tetrahydropyran modified nucleoside wherein a tetrahydropyran ring replaces the furanose ring.

17. The compound of any one of claims 1-13, wherein at least one nucleoside comprises a modified nucleobase such as a 5'-methylcytosine.

18. The compound of claim 17, wherein each cytosine within the nucleobase sequence is a 5'-methylcytosine.

19. The compound of any one of claims 1 to 18, wherein the modified oligonucleotide comprises:

(a) a gap segment consisting of thirteen linked deoxynucleosides;

(b) a 5' wing segment consisting of two linked modified nucleosides; and

(c) a 3' wing segment consisting of five linked modified nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each modified nucleoside within each wing segment comprises a 2'-O-methoxyethyl sugar; and wherein each internucleoside linkage is a phosphothioate linkage.

20. The compound of any one of claims 1 to 19, wherein the modified oligonucleotide consists of 20 linked nucleosides, and wherein the nucleobase sequence is the sequence set forth in SEQ ID NO: 39, 40, or 166.

21. The compound of claim 20, wherein the nucleobase sequence is the sequence set forth in SEQ ID NO: 39.

22. A compound which comprises a modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence as recited in SEQ ID NO: 39, wherein the modified olignucleotide comprises:

(a) a gap segment consisting of thirteen linked deoxynucleosides;

(b) a 5' wing segment consisting of two linked modified nucleosides; and

(c) a 3' wing segment consisting of five linked modified nucleosides;

wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment,

wherein each modified nucleoside within each wing segment comprises a 2’-O-methoxyethyl sugar,

wherein each internucleoside linkage is a phosphorothloate linkage, and

wherein each cytosine nucleobase is a 5’-methylcytosine.

23. A compound which comprises a modified oligonucleotide comprising at least 12 linked nucleosides, the nucleobase sequence of which is present within the nucleobase sequences set forth in any one of SEQ ID NOs: 39, 40, and 166, wherein the modified oligonucleotide comprises:

(a) a gap segment consisting of linked deoxynucleosides;

(b) a 5’ wing segment consisting of linked modified nucleosides; and

(c) a 3’ wing segment consisting of linked modified nucleosides;

wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment and wherein each modified nucleoside within each wing segment comprises a modified sugar.

24. The compound of claim 23, wherein the nucleobase sequence is set forth in SEQ ID NO: 39.

25. An antisense oligonucleotide consisting of the nucleotide sequence of SEQ ID NO: 39, said antisense oligonucleotide further characterized as having, from 5’ to 3’ direction,

a 5′ wing segment consisting of two nucleotides, a gap segment consisting of 13 nucleotides, and a 3′ wing segment consisting of five nucleotides,

wherein each nucleotide of said 5’ and 3’ wing segments comprises a 2′-O-methoxyethyl sugar,

wherein each nucleotide of said gap segment comprises a deoxyribose sugar,

wherein each cytosine base of said antisense oligonucleotide is a 5’-methylcytosine, and

wherein the internucleotide linkages between each nucleotide of said antisense oligonucleotide are phosphorothioate linkages.

26. A composition which comprises a compound of any of claims 1-24 or an antisense oligonucleotide of claim 25, or a pharmaceutically acceptable salt of such compound or of such oligonucleotide and a pharmaceutically acceptable carrier or diluent.

27. A composition comprising the compound of any of claims 1-24 or an antisense oligonucleotide of claim 25 formulated for topical administration.

28. A composition comprising the compound of any of claims 1-24 or an antisense oligonucleotide of claim 25 formulated for subcutaneous administration.

29. A composition comprising the compound of any of claims 1-24 or an antisense oligonucleotide of claim 25 formulated for local administration.

30. A composition comprising the compound of any of claims 1-24 or an antisense oligonucleotide of claim 25 formulated for intradermal administration.

31. The compound of any one of claims 1-24, the composition of any one of claims 26-30, or the antisense oligonucleotide of claim 25, for use as a medicament.

32. The compound of any of claims 1-24, the composition of any of claims 26-30, or the antisense oligonucleotide of claim 25, for use in treating an animal having a disease or condition associated with expression of connective tissue growth factor, preferably wherein the disease or condition is a hyperproliferative disorder; a cancer; a fibrotic disease such as hypertrophic scarring, keloids, skin scarring, liver fibrosis, pulmonary fibrosis, renal fibrosis, cardiac fibrosis, or restenosis; or joint fibrosis (including frozen shoulder syndrome, tendon and peripheral nerve damage), spinal cord damage, coronary bypass, abdominal and peritoneal adhesions (including

endometriosis, uterine leiomyomata and fibroids), radial keratotomy and photorefractive keratectomy, retinal reattachment surgery, device mediated fibrosis (in for example diabetes), tendon adhesions, Dupuytren contracture, or scleroderma.

33. The compound of any of claims 1-24, the composition of any of claims 26-30, or the antisense oligonucleotide of claim 25, for use in reducing scarring resulting from wound healing in a subject in need thereof, wherein the wound healing is healing at a wound selected from the group consisting of skin breakage, surgical incisions, and burns.